Using dapagliflozin to prevent kidney injury from worsening
Official title: Potential Use of Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
Run by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · NCT05713851 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if adding dapagliflozin to regular treatment can help hospitalized patients with severe acute kidney injury avoid developing chronic kidney disease.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Academic / other |
| Locations | 1 site (Mexico City) |
| Trial ID | NCT05713851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old who have been hospitalized with a diagnosis of severe AKI for less than 24 hours.
✕Probably not a fit
Patients with pre-existing chronic kidney disease, certain acute conditions, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness and safety of dapagliflozin, combined with standard medical treatment, in hospitalized patients diagnosed with severe acute kidney injury (AKI). The study aims to determine if this intervention can reduce the transition from AKI to chronic kidney disease (CKD) over an 18-month follow-up period. A total of 100 patients will be randomly assigned to receive either dapagliflozin or standard care for 21 days. The trial is designed as a randomized, single-center, open-label study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of developing chronic kidney disease in patients who have experienced acute kidney injury.
How similar studies have gone: Other studies have explored similar therapeutic strategies, but this specific approach using dapagliflozin in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (aged \>18 years) with AKI 3 diagnosis for less than 24 h (KDIGO classification, creatinine level or urine output criteria), hospitalized in general admission floor and/or intensive care unit. AKI diagnosis must be compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression. Exclusion Criteria: * CKD Stage 3b (KDIGO) or more, renal transplant, urinary tract obstruction, thrombotic microangiopathy, acute glomerulopathy, cardiac arrest without awakening, oncological diagnosis with a life expectancy of less than 5 years, use of norephinephrine \>0.30 mcg/kg/min for 6 h or more, use of two vasopressors, PaO2/FiO2 ratio \<150, Type 1 DM, fasting for more than 48 h, previous inclusion in other study, pregnant or breastfeeding woman.
Where it's running
-
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping
This project tests a Renal dining map app to help CKD patients in Singapore choose foods when dining out and see if it improves empowerment and well‑being.
-
Self-Management Data and Disease Progression in CKD
This study tests whether patient-recorded self-management data collected via a mobile app can be linked to CKD progression in adults seen at a university hospital.
-
Enarodustat for Anemia in Non-Dialysis CKD Patients
This study tests whether enarodustat can help increase hemoglobin safely in adults with CKD who aren’t on dialysis, grouping participants by inflammation level.
-
SP16 to help prevent kidney injury during cardiac surgery in people with CKD
Researchers are testing SP16 to see if it can prevent acute kidney injury in adults with chronic kidney disease who are having heart surgery that uses a heart-lung machine.
-
Periodontal Health in Rare Kidney Conditions and Controls
This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.
-
AdiaVita regenerative therapy for chronic kidney disease
This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.